BAC and Octapharma Extend Recombinant Factor IX Collaboration for Clinical and Commercial Scale Production

04-Nov-2009 - Netherlands

BAC BV announced that it has entered into a licence agreement with Octapharma to use BAC’s anti-factor IX CaptureSelect® affinity ligand in the large scale purification of recombinant Factor IX (FIX). Octapharma produces FIX for the treatment of bleeding in Haemophilia B. The licence agreement follows on from successful completion of feasibility studies. Concurrently, the companies have embarked on a new discovery programme under which BAC will develop a CaptureSelect affinity ligand for the purification of recombinant human granulocyte-colony stimulating factor (G-CSF), which has applications in oncology and haematology.

Under the terms of the FIX agreement Octapharma will have licence to use BAC’s anti-FIX ligand for the purification of FIX from mammalian cell culture. Under the terms of the G-CSF agreement BAC will perform ligand discovery and development to provide an anti-G-CSF ligand, which will then undergo feasibility studies at Octapharma.

“The progression of the Factor IX programme from feasibility study to scale up, and the initiation of the G-CSF project, are significant in our ongoing relationship with Octapharma,” said Dr Laurens Sierkstra, CEO of BAC. “All the team here at BAC are delighted that our anti-FIX ligand has proven to be such a good fit for Octapharma’s downstream processes, and we are looking forward to working on its scale-up and developing a new affinity ligand for G-CSF.”

https://www.bionity.com/en/news/108835/bac-and-octapharma-extend-recombinant-factor-ix-collaboration-for-clinical-and-commercial-scale-production.html